Peiseler, Moritz, MD (B04)

Personal Data

Title	Dr. med.
First name	Moritz
Name	Peiseler
Current position	BIH Clinician Scientist Fellow / Resident Internal Medicine
Current institution(s)/site(s), country	Department of Hepatology and Gastroenterology Charité – Universitätsmedizin Berlin, Campus Charité Mitte (CCM) and Campus Virchow-Klinikum (CVK), Augustenburger Platz 1, 13353 Berlin, Germany
Identifiers/ORCID	ORCID-ID: 0000-0001-6195-3866

Qualifications and Career

Stages	**Periods and Details**
Degree programme: Medicine	2008 – 2013, University of Hamburg, Germany (clinical electives: McGill University, Montreal, Canada; University of Sydney, Sydney, Australia)
Doctorate: MD thesis	05.12.2014: Supervisor: Christoph Schramm; *"Function and frequency of regulatory T cells in patients with Autoimmune Hepatitis";* University of Hamburg, Hamburg, Germany
Stages of academic/ professional career	
Since 2021	Internal Medicine and Gastroenterology Residency, Dept. of Hepatology and Gastroenterology, Charité – Universitätsmedizin Berlin, Campus Charité Mitte (CCM) and Campus Virchow-Klinikum (CVK), Berlin, Germany
Since 2021	BIH (Berlin Institute of Health) Clinician Scientist Fellow, Charité – Universitätsmedizin Berlin, Berlin, Germany
2017 – 2021	Postdoctoral Fellow (DFG stipend), Snyder Institute for Chronic Diseases (Supervisor: Paul Kubes), University of Calgary, Calgary, Canada
2016 – 2017	Clinician Scientist Fellowship; Faculty of Medicine, University Hospital Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany
2013 – 2017	Internal Medicine Residency, University Hospital Hamburg-Eppendorf, I. Department of Medicine (Gastroenterology, Hepatology & Infectious Diseases), University of Hamburg, Hamburg, Germany
2009 – 2010	DFG-funded Graduate School *"Inflammation & Regeneration"*, Faculty of Medicine, University of Hamburg, Hamburg, Germany

Supplementary Career Information

- 2004 – 2006 career as professional basketball player

Engagement in the Research System

- Guidelines: member of DGVS guideline on rare liver diseases (LeiSe LebEr)
- Peer reviewing for Journal of Hepatology
- Poster Prize Committee and Poster discussion (section Autoimmune Liver Diseases), GASL Meeting 2022

Scientific Results

Category A, * contributed equally, # open access

1. Heymann F*, Mossanen JC*, **Peiseler M***, Niemietz PM, Araujo David B, Krenkel O, Liepelt A, Batista Carneiro M, Kohlhepp MS, Kubes P, Tacke F. Hepatic C-X-C chemokine receptor type 6-expressing innate lymphocytes limit detrimental myeloid hyperactivation in acute liver injury. **Hepatol Commun** 2023; 7(4):e0102. doi: 10.1097/HC9.0000000000000102. # This is my first paper from Berlin where we used imaging to understand innate lymphocytes in acute liver failure.
2. **Peiseler M**, Schwabe R, Hampe J, Kubes P, Heikenwälder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. **J Hepatol** 2022; 77(4):1136-1160. doi: 10.1016/j.jhep.2022.06.012.
3. Zindel J, **Peiseler M**, Hossain M, Deppermann C, Lee WY, Haenni B, Zuber B, Deniset JF, Surewaard BGJ, Candinas D, Kubes P. Primordial GATA6 macrophages function as extravascular platelets in sterile injury. **Science** 2021; 371(6533):eabe0595. doi: 10.1126/science.abe0595. I contributed significantly with the liver data of peritoneal macrophages to help get this paper published.
4. Deppermann C*, **Peiseler M***, Zindel J, Zbytnuik L, Lee WY, Pasini E, Baciu C, Matelski J, Lee Y, Kumar D, Humar A, Surewaard B, Kubes P, Bhat M. Tacrolimus Impairs Kupffer Cell Capacity to Control Bacteremia: Why Transplant Recipients Are Susceptible to Infection. **Hepatology** 2021; 73(5):1967-1984. doi: 10.1002/hep.31499.
5. Malehmir M, Pfister D, Gallage S, Szydlowska M, Inverso D, Kotsiliti E, Leone V, **Peiseler M**, Surewaard BGJ, Rath D, Ali A, Wolf MJ, Drescher H, Healy ME, Dauch D, Kroy D, Krenkel O, Kohlhepp M, Engleitner T, Olkus A, Sijmonsma T, Volz J, Deppermann C, Stegner D, Helbling P, Nombela-Arrieta C, Rafiei A, Hinterleitner M, Rall M, Baku F, Borst O, Wilson CL, Leslie J, O'Connor T, Weston CJ, Chauhan A, Adams DH, Sheriff L, Teijeiro A, Prinz M, Bogeska R, Anstee N, Bongers MN, Notohamiprodjo M, Geisler T, Withers DJ, Ware J, Mann DA, Augustin HG, Vegiopoulos A, Milsom MD, Rose AJ, Lalor PF, Llovet JM, Pinyol R, Tacke F, Rad R, Matter M, Djouder N, Kubes P, Knolle PA, Unger K, Zender L, Nieswandt B, Gawaz M, Weber A, Heikenwalder M. Platelet GPIba is a mediator and potential interventional target for NASH and subsequent liver cancer. **Nat Med** 2019; 4:641-655. doi: 10.1038/s41591-019-0379-5. # This paper was a collaboration with Mathias Heikenwälders group and is listed here as I feel I provided some key mechanistic findings using intravital microscopy (all of Fig. 4 and parts of Fig. 6). As a result, I am listed as a shared second author. Furthermore, we provide first evidence that intravital works in fatty liver.

6. **Peiseler M***, Reiners D*, Pinnschmidt HO, Sebode M, Jung F, Hartl J, Zenouzi R, Ehlken H, Groth S, Schachschal G, Roesch T, Weiler-Normann C, Lohse AW, Schramm C. Risk of endoscopic biliary interventions in patients with primary sclerosing cholangitis is similar between patients with and without cirrhosis. **Plos One** 2018; 13(8):e0202686. doi: 10.1371/journal.pone.0202686. #
7. **Peiseler M***, Liebscher T*, Sebode M, Zenouzi R, Hartl J, Ehlken H, Pannicke N, Weiler-Normann T, Lohse AW, Schramm C. Efficacy and limitations of Budesonide as a Second-line Treatment for Patients with Autoimmune Hepatitis. **Clin Gastroenterol Hepatol** 2018; 16(2):260-267. doi: 10.1016/j.cgh.2016.12.040.
8. **Peiseler M**, Creutzfeldt A, Cassens I, Glaubke C, Kroll C, Lohse AW, Weiler-Normann C. Potential impact of screening for fatty liver disease by transient elastography with liver stiffness and controlled attenuation parameter measurements: a pilot study. **Z Gastroenterol** 2017; 55:754-760. doi: 10.1055/s-0043-111804.
9. Sebode M*, **Peiseler M***, Franke B, Schwinge D, Schoknecht T, Wortmann F, Quaas A, Petersen BS, Ellinghaus E, Baron U, Olek S, Wiegard C, Weiler-Normann C, Lohse AW, Herkel J, Schramm C. Reduced FOXP3(+) regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms. **J Hepatol** 2014; 60:1010-1016. doi: 10.1016/j.jhep.2013.12.027.
10. **Peiseler M***, Sebode M*, Franke B, Wortmann F, Schwinge D, Quaas A, Baron U, Olek S, Wiegard C, Lohse AW, Weiler-Normann C, Schramm C, Herkel J. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. **J Hepatol** 2012; 57:125 – 132. doi: 10.1016/j.jhep.2012.02.029.

Category B

1. “Endoscopic treatment in patients with primary sclerosing cholangitis and established cirrhosis is not associated with an increased rate of complications”, oral presentation at the 52nd ILC (international liver congress, annual EASL Meeting) (2017)
2. “Budesonide for autoimmune hepatitis: response rate and limitations in a large real life cohort”, oral presentation at the 50th ILC (international liver congress, annual EASL Meeting) (2015)
3. “The frequencies of Foxp3+ regulatory T cells in livers and peripheral blood of type I autoimmune hepatitis patients correlate with inflammatory activity”, oral presentation at the 61st Annual Meeting of the AASLD (American Association for the Study of Liver Diseases) (2010)

Academic Distinctions

- BIH (Berlin Institute of Health) Clinician Scientist Fellowship (2021)
- DFG-funded Postdoctoral Research Fellowship (2017 – 2021)
- Young investigator travel grants EASL (European Association for the Study of the Liver) (2015, 2017)
- Clinician Scientist Fellowship, Medical Faculty University of Hamburg (2016)
- Award “Student of the year” by the Medical Faculty of the University of Hamburg for best first author publication by a medical student (2012)

- Dissertation Scholarship, DFG-funded Graduate School “Inflammation & Regeneration” (2009 – 2010)

Fields of Research

No.	Fields of research
1	205-15 Medicine/**Gastroenterology**
2	201-03 Basic Research in Biology and Medicine/**Cell Biology**
3	204-05 **Immunology**